Qiagen NV | QIA - Gross Profit On Sales


Qiagen NV reported $325.27M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
argenx SE USD 1.18B 40.98M Mar/2026
Avita Medical AUD 14.31M 639K Dec/2025
Dianthus Therapeutics USD 463K 179K Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
IQVIA Holdings USD 1.07B 52M Mar/2026
Moderna USD -566M 792M Mar/2026
Organon & Co USD 783M 71M Mar/2026
Qiagen NV USD 325.27M 19.53M Dec/2025
Revvity USD 387.66M 34M Mar/2026
Tectonic Therapeutic USD 0 0 Mar/2025
Viatris USD 1.38B 229.9M Mar/2026
Xeris Pharmaceuticals USD 72.55M 404K Mar/2026